adpenetrance
adpenetrance estimates the penetrance of genetic variants associated with autosomal dominant traits to quantify the probability that carriers express the phenotype for genetic risk assessment and research.
Key Features:
- Population-scale data utilization: Leverages population-scale data to estimate penetrance, enabling robust analysis when large family pedigrees are unavailable and for rare, late-onset, or complex diseases.
- Case-control and affected-only inputs: Employs a method that uses data from both affected (cases) and unaffected (controls) individuals and can operate using affected-only samples by incorporating family disease history.
- Validation and consistency: Validated through simulation studies and produces estimates consistent with existing knowledge and established methods.
- Bias resilience: Circumvents limitations of kinship-specific penetrance estimates and reduces ascertainment biases to provide more generalized penetrance estimates for autosomal dominant traits.
Scientific Applications:
- Genetic Counseling: Provides penetrance-based risk assessments to inform counseling for individuals and families carrying pathogenic variants.
- Disease Research: Enhances understanding of the genetic basis of diseases by quantifying variant-specific penetrance for research studies.
- Gene Therapy: Informs evaluation of potential therapeutic interventions by providing penetrance estimates for target variants.
Methodology:
Analyzes population-scale case-control data, can incorporate family disease history for affected-only samples, and uses simulation studies for validation while addressing kinship-specific limitations and ascertainment biases.
Topics
Details
- Tool Type:
- web application
- Programming Languages:
- R
- Added:
- 6/14/2021
- Last Updated:
- 8/9/2021
Operations
Publications
Spargo TP, Opie-Martin S, Lewis CM, Iacoangeli A, Al-Chalabi A. Calculating variant penetrance using family history of disease and population data Authorship. Unknown Journal. 2021. doi:10.1101/2021.03.16.21253691.